Department of Ophthalmology, Rabin Medical Center, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Indian J Ophthalmol. 2024 Feb 1;72(Suppl 2):S248-S253. doi: 10.4103/IJO.IJO_1042_23. Epub 2023 Dec 26.
To study the long-term clinical outcome and treatment strategies of recurrent and chronic non-infectious anterior uveitis.
Multicenter study of anterior uveitis patients from 2001 to 2022. Outcome measures included ocular complications, medical and surgical therapies, and visual acuity measured at the beginning of follow-up and at 1, 2, and 5 years thereafter.
In total, 76 patients were included, with a mean follow-up of 6.8 years. Idiopathic anterior uveitis was the most common etiology (56%). Immunomodulatory agents (IMAs) were used in almost half of the cohort. Early initiation of IMAs was associated with a lower risk of developing glaucoma ( P = 0.019). Mean best corrected visual acuity (BCVA) improved after 5 years in both groups. Early use of immunomodulation was correlated with a better visual outcome at 2 years ( P = 0.024).
Chronic and recurrent anterior uveitis were associated with greater risk than expected for ocular complications, surgeries, and vision impairment. Early initiation of immunomodulation should be strongly considered to improve clinical course and outcome.
研究复发性和慢性非感染性前葡萄膜炎的长期临床结果和治疗策略。
对 2001 年至 2022 年间的前葡萄膜炎患者进行多中心研究。主要结局指标包括眼部并发症、药物和手术治疗以及随访开始时和此后 1、2 和 5 年的视力。
共纳入 76 例患者，平均随访 6.8 年。特发性前葡萄膜炎是最常见的病因（56%）。近一半的患者使用了免疫调节剂（IMAs）。早期使用 IMA 与发生青光眼的风险降低相关（P=0.019）。两组患者在 5 年后的最佳矫正视力（BCVA）均有所提高。早期免疫调节与 2 年时更好的视力结果相关（P=0.024）。
慢性和复发性前葡萄膜炎比预期更易发生眼部并发症、手术和视力损害。早期使用免疫调节剂应被强烈考虑以改善临床病程和结局。
